Cargando…
Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utili...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581659/ https://www.ncbi.nlm.nih.gov/pubmed/33090273 http://dx.doi.org/10.1186/s13550-020-00720-3 |
_version_ | 1783599018134208512 |
---|---|
author | Lawhn-Heath, Courtney Yom, Sue S. Liu, Chienying Villanueva-Meyer, Javier E. Aslam, Maya Smith, Raven Narwal, Manpreet Juarez, Roxanna Behr, Spencer C. Pampaloni, Miguel Hernandez Chan, Jason W. Glastonbury, Christine M. Hope, Thomas A. Flavell, Robert R. |
author_facet | Lawhn-Heath, Courtney Yom, Sue S. Liu, Chienying Villanueva-Meyer, Javier E. Aslam, Maya Smith, Raven Narwal, Manpreet Juarez, Roxanna Behr, Spencer C. Pampaloni, Miguel Hernandez Chan, Jason W. Glastonbury, Christine M. Hope, Thomas A. Flavell, Robert R. |
author_sort | Lawhn-Heath, Courtney |
collection | PubMed |
description | BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [(68)Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. METHODS: Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[(18)F]FDG PET and/or (131)I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [(68)Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[(18)F]FDG PET CT/MRI for lesion location and relative intensity. RESULTS: Twelve patients underwent [(68)Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[(18)F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[(18)F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. CONCLUSIONS: [(68)Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[(18)F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients. |
format | Online Article Text |
id | pubmed-7581659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-75816592020-10-26 Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study Lawhn-Heath, Courtney Yom, Sue S. Liu, Chienying Villanueva-Meyer, Javier E. Aslam, Maya Smith, Raven Narwal, Manpreet Juarez, Roxanna Behr, Spencer C. Pampaloni, Miguel Hernandez Chan, Jason W. Glastonbury, Christine M. Hope, Thomas A. Flavell, Robert R. EJNMMI Res Original Research BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [(68)Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. METHODS: Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[(18)F]FDG PET and/or (131)I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [(68)Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[(18)F]FDG PET CT/MRI for lesion location and relative intensity. RESULTS: Twelve patients underwent [(68)Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[(18)F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[(18)F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. CONCLUSIONS: [(68)Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[(18)F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients. Springer Berlin Heidelberg 2020-10-22 /pmc/articles/PMC7581659/ /pubmed/33090273 http://dx.doi.org/10.1186/s13550-020-00720-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Lawhn-Heath, Courtney Yom, Sue S. Liu, Chienying Villanueva-Meyer, Javier E. Aslam, Maya Smith, Raven Narwal, Manpreet Juarez, Roxanna Behr, Spencer C. Pampaloni, Miguel Hernandez Chan, Jason W. Glastonbury, Christine M. Hope, Thomas A. Flavell, Robert R. Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title | Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title_full | Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title_fullStr | Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title_full_unstemmed | Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title_short | Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study |
title_sort | gallium-68 prostate-specific membrane antigen ([(68)ga]ga-psma-11) pet for imaging of thyroid cancer: a feasibility study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581659/ https://www.ncbi.nlm.nih.gov/pubmed/33090273 http://dx.doi.org/10.1186/s13550-020-00720-3 |
work_keys_str_mv | AT lawhnheathcourtney gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT yomsues gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT liuchienying gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT villanuevameyerjaviere gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT aslammaya gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT smithraven gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT narwalmanpreet gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT juarezroxanna gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT behrspencerc gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT pampalonimiguelhernandez gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT chanjasonw gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT glastonburychristinem gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT hopethomasa gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy AT flavellrobertr gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy |